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Attention-Deficit/Hyperactivity Disorder (ADHD) is a childhood psychiatric disorder often
comorbid with disruptive behavior disorders (DBDs). Here, we report a GWAS meta-analysis
of ADHD comorbid with DBDs (ADHD+DBDs) including 3802 cases and 31,305 controls.
We identify three genome-wide significant loci on chromosomes 1, 7, and 11. A meta-analysis
including a Chinese cohort supports that the locus on chromosome 11 is a strong risk locus for
ADHD+DBDs across European and Chinese ancestries (rs7118422, P= 3.15×10−10, OR=
1.17). We find a higher SNP heritability for ADHD+DBDs (h2SNP= 0.34) when compared to
ADHD without DBDs (h2SNP= 0.20), high genetic correlations between ADHD+DBDs and
aggressive (rg= 0.81) and anti-social behaviors (rg= 0.82), and an increased burden
(polygenic score) of variants associated with ADHD and aggression in ADHD+DBDs
compared to ADHD without DBDs. Our results suggest an increased load of common risk
variants in ADHD+DBDs compared to ADHD without DBDs, which in part can be explained
by variants associated with aggressive behavior.
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Attention-Deficit/Hyperactivity Disorder (ADHD) is acommon childhood onset behavioral disorder affectingaround 5% of children and 2.5% of adults1. Comorbidity
with other psychiatric disorders is common among children with
ADHD, and disruptive behavior disorders (DBDs) are the most
frequently co-occurring conditions2. DBDs comprise oppositional
defiant disorder and conduct disorder. Both have a childhood
onset and are characterized by persistent patterns of oppositional,
defiant, disobedient and disruptive behavior and antisocial rule-
breaking, and aggressive behaviors such as being destructive,
physically cruel towards others, and rule violations3. DBDs have a
prevalence of 3–10%4,5 among children and, are around twice as
frequent in males compared to females6 and DBDs are associated
with a 3-fold increased risk of premature death7, with higher
mortality rates than in ADHD8. Different comorbidity rates of
ADHD with DBDs have been reported, some studies have found
that approximately 30–40% of children with ADHD have
comorbid DBDs (ADHD+DBDs)9–11, while a study of 1.92
million individuals from Denmark found that 17% of those with
ADHD were also diagnosed with DBDs8. Among those with
DBDs in the same Danish cohort, more than half (57%) had a
comorbid diagnosis of ADHD7. ADHD in combination with
diagnosed DBDs or excessive aggressive and disruptive behaviors
increases the risk for several detrimental outcomes in individuals
with ADHD including increased risks for substance use dis-
orders12–14, in-patient psychiatric admission15, transgression16,17,
risky behavior18, and premature death compared to those diag-
nosed with ADHD only8.
Both genetic and environmental factors influence the risk for
ADHD and DBDs with twin heritability estimates of 0.7419 and
0.40–0.7020–22, respectively. Twin studies have also suggested that
ADHD+DBDs is a more severe and genetically loaded subtype
of ADHD than ADHD without comorbid DBDs23. Siblings of
individuals with ADHD+DBDs have a higher recurrence risk to
develop ADHD+DBDs compared to siblings of individuals
having ADHD without DBDs (ADHDwoDBDs)24,25. Individuals
with ADHD+DBDs also have an increased polygenic burden of
common ADHD risk variants compared to individuals with only
ADHD, further supporting the hypothesis that ADHD+DBDs
reflect a higher load of genetic risk26. However, it seems unlikely
that ADHD risk variants alone can fully account for the under-
lying genetic risk that mediates aggressive and disruptive beha-
viors in individuals with ADHD+DBDs. Family studies have
found that ADHD and DBDs have distinct genetic architectures
with moderate to high genetic overlap in the range of
0.34–0.7427–29. The existence of genetic risk factors specific to the
aggressive and disruptive component of ADHD+DBDs finds
support from a twin study, where DBDs had an estimated her-
itability of 0.33–0.64 after controlling for ADHD30.
Several genome-wide association studies (GWASs) have
focused on diagnosed DBDs31,32 or aggressive and anti-social
behaviors33,34, with only limited success in identifying genome-
wide significant loci and no conclusive, replicated findings31,33,34.
Only two genome-wide studies have focused specifically on
ADHD+DBDs. One small genome-wide linkage study examined
DBDs in individuals with ADHD35 and another, while not
assessing diagnosed DBDs, examined aggressive behaviors in
individuals with ADHD36. Neither studies reported genome-wide
significant loci.
In the current study we perform a large GWAS meta-analysis
of ADHD+DBDs using a Danish nation-wide cohort from
iPSYCH and samples from the Psychiatric Genomics Consortium
(PGC). We identify three genome-wide significant loci for
ADHD+DBDs, located on chromosomes 1, 7, and 11, and show
evidence of transancestral association for the locus on chromo-
some 11 in a Chinese cohort and, we find high polygenic overlap
of ADHD+DBDs with childhood aggression and antisocial
behavior in the general population, higher than found for
ADHDwoDBDs.
Results
GWAS meta-analysis of ADHD+DBDs. The meta-analysis
included data from the Danish iPSYCH cohort (2155 cases,
22,664 controls) and six European ancestry PGC cohorts (1647
cases, 8641 controls). All cases were diagnosed with both ADHD
and DBDs or had a diagnosis of hyperkinetic conduct disorder,
which according to the ICD10 criteria implies that both disorders
are present. Selection of controls was population-based and
they were not diagnosed with either ADHD or DBDs. Results
were in total based on 3802 cases and 31,305 controls and
included 8,285,688 variants after filtering. Three loci passed the
threshold for genome-wide significance (P= 5 × 10−8); these
were located on chromosome 1 (index variant rs549845, P=
2.38 × 10−8, OR= 1.16), 7 (index variant rs11982272, P= 4.38 ×
10−8, OR= 0.83), and 11 (index variant, rs7118422, P= 8.97 ×
10−9, OR= 1.16) (Table 1, Fig. 1a and Supplementary
Fig. 1A–C). The directions of association of the index variants in
the three loci were consistent across all cohorts (Supplementary
Fig. 2A–C).
Homogeneity of effects in the PGC and iPSYCH cohorts and
intercept evaluation. To evaluate the consistency of the genetic
architecture underlying ADHD+DBDs in iPSYCH and PGC
cohorts, we estimated the genetic correlation between the two
using LD score regression37,38. The genetic correlation between
the iPSYCH cohort and the meta-analyzed PGC cohorts was high
(rg= 0.934, SE= 0.14, P= 3.26 × 10−11) supporting consistency
of the ADHD+DBDs phenotypes analyzed in the cohorts. In
addition, no variants demonstrated significant heterogeneity
between studies (Supplementary Figs. 3 and 4).
LD score regression analysis indicated that the observed
deviation of the genome-wide test statistics from the null
distribution (lambda= 1.11, Fig. 1b) was mainly caused by
polygenicity. The intercept ratio estimate suggests that the
majority of the inflation of the mean χ2 statistic of the GWAS
meta-analysis is attributable to polygenic effects (ratio= 0.12,
SE= 0.0662) rather than confounding factors. The estimated
remaining contribution of confounding factors was small and
non-significant (intercept= 1.015; SE= 0.008; P= 0.064).
Transancestry GWAS meta-analysis across European and Han
Chinese ancestry. To replicate and generalize the findings to
other ethnicities, a GWAS of ADHD+DBDs was performed in a
Han Chinese cohort (referred to as the Chinese cohort (406 cases,
917 controls; Supplementary Fig. 5). Of the three loci identified in
the main analysis, the locus on chromosome 11 was nominally
significant in the Chinese cohort (P= 0.006, Supplementary
Fig. 8C). A fixed effects meta-analysis including the Chinese,
European iPSYCH and PGC cohorts was performed in total
including 4208 cases and 32,222 controls (no variants demon-
strated significant heterogeneity across European and Chinese
ancestries, Supplementary Figs. 6 and 7). For the locus on chro-
mosome 11 the association P-value became stronger in the trans-
ancestry GWAS meta-analysis (P= 3.15 × 10−10, OR= 1.17)
(Fig. 2 and Supplementary Data 1, Supplementary Fig. 9), sug-
gesting the locus is a risk locus for ADHD+DBDs across eth-
nicities. The results incorporating the Chinese cohort did not
support replication of the other two loci (Table 1).
Secondary GWASs. For subsequent evaluation of how much
of the signal in the GWAS meta-analysis of ADHD+DBDs
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was driven by the oppositional/aggressive component of
the comorbid phenotype, two additional GWASs were con-
ducted using iPSYCH samples. To adjust for the effect of
ADHD, we performed a case-only GWAS comparing 1959
individuals with ADHD+DBDs against 13,539 individuals
having ADHDwoDBDs, referred to as the “ADHD+DBDs vs.
ADHDwoDBDs GWAS”. Additionally, a GWAS of 13,583 cases
having ADHDwoDBDs and 22,314 population-based controls,
referred to as the “ADHDwoDBDs GWAS”, was performed
(the case–control numbers differ between GWASs due to
deviation in the numbers of related individuals and genetic
outliers removed in the analyses).
The summary statistics from the two secondary GWASs were
used to evaluate the direction of association of the top loci (281
loci, P < 1 × 10−4) from the GWAS meta-analysis of ADHD+
DBDs. A consistent direction of association was observed for
221 loci (out of the 281 loci) in the ADHDwoDBDs GWAS
(sign test P < 2.2 × 10−16), while all the 281 loci demonstrated
consistent direction of association in the ADHD+DBDs vs.
ADHDwoDBDs GWAS. The proportion of variants having a
consistent direction of association in the ADHD+DBDs vs.
ADHDwoDBDs GWAS was significantly larger than the propor-
tion in the ADHDwoDBDs GWAS (P= 7.7 × 10−16), which
suggests that the associations in the GWAS meta-analysis of
ADHD+DBDs reflects association with the comorbid phenotype
beyond association with risk for ADHD alone.
All three genome-wide significant loci demonstrated higher
effect sizes in ADHD+DBDs compared to ADHDwoDBDs
(Supplementary Data 2). In particular, the effect sizes for the loci
located on chromosomes 7 and 11 (ORchr7=ORs 1.199; ORchr11
= 1.164) remained strong in the ADHD+DBDs vs.
ADHDwoDBDs GWAS (ORchr7 1.128; ORchr11= 1.126) con-
firming a stronger effect of the risk allele for these two loci in
ADHD+DBDs compared to ADHDwoDBDs (Supplementary
Data 2). The difference was most striking for rs7118422 on
chromosome 11 (ADHD+DBDs: OR= 1.164, P= 8.97 × 10−9),
which showed no evidence for association with ADHDwoDBDs
(OR= 1.022, P= 0.175) versus a suggestive evidence of associa-
tion with ADHD+DBDs vs. ADHDwoDBDs (OR= 1.126, P=
7.07 × 10−04).
To help formalize the comparison of ADHD+DBDs with
ADHDwoDBDs, we also used mtCOJO39 to estimate the joint
effects of the significant loci from the GWAS of ADHD+DBDs
conditional on effects mediated through the genetics of
ADHDwoDBDs. Under this model (see “Methods” section) none
of the three loci reached genome-wide significance for a direct
effect on ADHD+DBDs, although the locus on chromosome 11
retained the most robust signal after correction for
ADHDwoDBDs (ORadjusted= 1.14; Padjusted= 1.43 × 10−06,
Supplementary Data 3).
Gene-based association test. A gene-based association analysis
was performed using MAGMA40. Six genes (RRM1, STIM1,
MAML3, ST3GAL3, KDM4A, and PTPRF) were significantly
associated with ADHD+DBDs (P < 2.7 × 10−6 correcting for
18,553 genes analyzed; Supplementary Fig. 10 and Supplementary
Data 4). Three genes (ST3GAL3, KDM4A, and PTPRF) are
located in the genome-wide significant locus on chromosome 1,
and two genes (RRM1, STIM1) in the genome-wide significant
locus on chromosome 11. One gene (MAML3) located on chro-
mosome 4 had not been identified as a risk locus in the single
variant analysis.
To evaluate if the gene-based association signals reflected the
aggressive and disruptive component of the ADHD+DBDs
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most associated genes from the primary ADHD+DBDs GWAS
meta-analysis (P < 10−3, 79 genes) using the results from the two
secondary GWASs. The gene set was significantly associated with
ADHDwoDBDs (beta= 0.312 (SE= 0.02), P= 9 × 10−4), but
had a stronger association in the ADHD+DBD vs. ADHD only
GWAS (beta= 1.1 (SE= 0.07), P= 9.28 × 10−32).
Association of genetically regulated gene expression with
ADHD+DBDs. Association of the genetically regulated gene
expression with ADHD+DBDs was analyzed in 12 brain tissues
from GTEx41 (version 6p) using MetaXcan42. Depending on the
tissue, 2042–6094 genes were tested (Supplementary Data 5).
Three genes were predicted to be differently expressed in ADHD
+DBDs cases compared with controls after Bonferroni correc-
tion (correcting for the total number of tests performed (43,142);
P < 1.16 × 10−6); RRM1 (chromosome 11) was less expressed in
cases, while RAB3C (chromosome 5) and LEPRE1 (chromosome
1) showed a higher expression in cases when compared to con-
trols (Supplementary Data 5). The genes on chromosome 1 and
11 were located in or near genome-wide significant loci, whereas
the gene on chromosome 5 was novel.
SNP heritability. SNP heritability (h2SNP) was estimated using a
prevalence of ADHD+DBDs in the population of 1–2%, based
on studies reporting that around 20–40% of individuals with
ADHD have comorbid DBDs8–11. The estimated h2SNP for
ADHD+DBDs was 0.25 (SE= 0.03) using LD score regression37
with a prevalence estimate of 2% in the population (Supple-
mentary Data 6A). When considering only the iPSYCH cohort, a
higher SNP heritability was found for ADHD+DBDs (h2SNP=
0.34; SE= 0.05) compared to ADHDwoDBDs (h2SNP= 0.20;
SE= 0.02). This pattern remained similar when using GCTA and
was stable when assuming a lower prevalence of ADHD+DBDs
(1%) and higher prevalence of ADHDwoDBDs (3%) (Supple-
mentary Data 6A). The h2SNP estimate was significantly higher for
ADHD+DBDs compared to ADHDwoDBDs in GCTA analyses
of independent iPSYCH samples, with Pdifference= 5.36 × 10−6
when assuming a prevalence of 2% for ADHD+DBDs and 3%
for ADHDwoDBDs (Supplementary Data 6B). Additionally,
common variants explained a small fraction of the variation in
the ADHD+DBDs phenotype compared to the ADHDwoDBDs
phenotype (GCTA h2SNP= 0.08; SE= 0.04; Supplementary
Data 6A).
Genetic correlation with aggression-related phenotypes. We
estimated the genetic correlations of ADHD+DBDs with
aggression-related phenotypes using GWAS results from analyses
of aggressive behaviors in 18,988 children33 (EAGLE aggression)
and antisocial behavior in 16,400 individuals34 (Broad Antisocial
Behavior Consortium (BroadABC)) using LD score regression37.
We found a high genetic correlation of ADHD+DBDs with
aggression in children (EAGLE aggression, rg= 0.81; SE= 0.24;
P= 0.001) and antisocial behavior (BroadABC, rg= 0.82; SE=
0.30; P= 0.007) (Supplementary Data 7). In contrast,
ADHDwoDBDs (analysed solely in iPSYCH) was only sig-
nificantly correlated with aggression in children (rg= 0.74; SE=
0.18; P= 4.6 × 10−5). Analyzing only the iPSYCH cohort,
ADHD+DBDs demonstrated a nominally higher positive
genetic correlation than ADHDwoDBDs with aggression in
children (rg= 0.85; SE= 0.24; P= 5 × 10−4; and rg= 0.74;
Fig. 1 Manhattan plot and quantile–quantile plot of results from the GWAS meta-analysis of ADHD + DBDs. A Results from GWAS meta-analysis of
iPSYCH and PGC cohorts in total including 3802 cases and 31,305 controls. The x-axis represents autosomal chromosomes colored in light and dark blue.
The y-axis represents two-sided P-values from meta-analysis using an inverse-variance weighted fixed effects model. The red horizontal line represents the
threshold for genome-wide significant association (P= 5 × 10−8). B Quantile–quantile (q–q) plot with expected −log10 P-values on the x-axis and −log10
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Fig. 2 Forest plot for the index variant in the genome-wide significant
locus for ADHD+DBDs on chromosome 11. Forest plot for the index
variant (rs7118422) in the genome-wide significant locus on chromosome
11. Visualization of the effect size estimates (natural logarithm of the odds
ratio (ln(OR)) in each included cohort, estimated from logistic regression,
and in the trans-ancestry GWAS meta-analysis of European and Chinese
cohorts (4208 cases and 32,222 controls) using an inverse-variance
weighted fixed effects model. In addition, standard errors of the ln(OR)
estimates. For information on sample sizes, allele frequencies and P-values
for rs7118422 in the single cohorts see Supplementary Data 1.
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SE= 0.18; P= 4.58 × 10−5, respectively) and antisocial behavior
(rg= 0.92; SE= 0.35; P= 9 × 10−3; and rg= 0.56; SE= 0.22; P=
0.01, respectively). The differences in the genetic correlations,
however, were not statistically significant when assessed using the
jackknife method43. Finally, we estimated the genetic correlation
of ADHD+DBDs vs ADHDwoDBDs (rg= 0.99, SE= 0.07, P=
2.64 × 10−45).
Polygenic score analysis of ADHD+DBDs compared to
ADHDwoDBDs. Case-only polygenic score (PGS) analyses were
done to evaluate whether ADHD+DBDs cases are enriched for
variants associated with 22 relevant phenotypes related to per-
sonality, cognition, and psychiatric disorders compared with
cases having ADHDwoDBDs. Seven phenotypes were sig-
nificantly associated with ADHD+DBDs compared with
ADHDwoDBDs after multiple testing correction (Supplementary
Data 8). Significantly increased PGS for aggressive behavior33
(Z= 4.80, P= 1.51 × 10−6, OR= 1.13) and ADHD (Z= 5.42, P
= 5.90 × 10−8, OR= 1.21) were observed for ADHD+DBDs.
Additionally, PGS for increased cognitive performance was
negatively associated with ADHD+DBDs compared to
ADHDwoDBDs (educational attainment44, Z=−3.30, P= 8.0 ×
10−4, OR= 0.92; college or university degree45 Z=−3.22, P=
1.0 × 10−3, OR= 0.93; human intelligence46 Z=−3.00, P=
2.00 × 10−3, OR= 0.93; verbal–numerical reasoning45 Z=−3.26,
P= 1.00 × 10−3, OR= 0.92). Finally, PGS for having children at
an older age was negatively associated with ADHD+DBDs
compared to ADHDwoDBDs (Z=−4.40, P= 8.4 × 10−6, OR=
0.9). Only a small proportion of the variance in ADHD+DBDs
among individuals with ADHD was explained by the PGSs, with
the maximum Nagelkerke’s R2= 0.36% for the ADHD PGS. The
odds ratio for ADHD+DBDs was increasing across quintiles of
the polygenic load of variants associated with aggression, and
ADHD, and decreasing with higher load of variants associated
with cognition and age at first birth (Supplementary Fig. 11A–G).
The highest risk was observed for ADHD PGS, where the 20% of
ADHD cases with the highest ADHD PGS had an OR= 2.48 for
having comorbid DBDs relative to the 20% with the lowest
ADHD PGS (Supplementary Figure 11A).
Discussion
This study identifies genome-wide significant loci for ADHD+
DBDs based on a meta-analysis of 3802 cases and 31,305 controls
from the iPSYCH cohort and six cohorts from PGC. We iden-
tified three risk loci on chromosomes 1, 7, and 11 with odds ratios
ranging from 1.16 to 1.20, in line with what was found in the
recent GWAS meta-analysis of ADHD47. These risk loci
demonstrated high consistency in the direction of association in
the included cohorts, indicating that the associations likely have a
biological cause rather than being spurious signals driven by one
or few cohorts (Fig. 2 and Supplementary Fig. 2A–C). The high
genetic correlation observed between the PGC cohorts and the
iPSYCH cohort suggests that the genetic architecture underlying
ADHD+DBDs were similar in the two samples. In the GWAS
meta-analysis for trans-ancestry risk of the identified loci in a
Chinese sample, only the locus on chromosome 11 replicated the
findings in the European samples. This locus seems to be speci-
fically associated with the aggressive and disruptive component of
the ADHD+DBDs phenotype, since the effect disappeared in
the ADHDwoDBDs GWAS. This was further supported in the
GWAS comparing comorbid ADHD+DBD to ADHDwoDBDs
where the locus remained strongly associated, although not
genome-wide significant (Supplementary Data 2). Consistent
with this, evidence for a direct effect of the locus on ADHD+
DBDs remained after adjusting for the effect of ADHDwoDBDs
in the mtCOJO analysis (Supplementary Data 3).
In contrast, the locus on chromosome 1, which was pre-
viously identified as a strong risk locus for ADHD47, seems to
reflect an association with ADHD. This locus remained genome-
wide significant in the GWAS of ADHDwoDBDs (Supplementary
Data 2) and the association with ADHD+DBDs decreased
considerably in the analyses adjusting for the effect of
ADHDwoDBDs and in the ADHD+DBDs vs. ADHDwoDBDs
GWAS (Supplementary Data 2 and 3).
The locus on chromosome 7 seems to be a shared risk locus
between ADHD+DBDs and ADHDwoDBDs. The locus
remained moderately associated in the GWASs adjusted for
ADHD (Supplementary Data 2 and 3) as well as in the
ADHDwoDBDs GWAS (Supplementary Data 2). The locus is
located in MAD1L1, which encodes a protein involved in mitotic
spindle-assembly checking before anaphase. The locus is novel
with respect to ADHD and DBDs, but was found genome-wide
significant in the recent large cross-disorder GWAS48 and has
previously been associated with schizophrenia and bipolar dis-
order49–51, suggesting that MAD1L1 is a risk gene for several
psychiatric disorders.
The locus most strongly associated with ADHD+DBDs on
chromosome 11 is located in STIM1 (Supplementary Fig. 1C), a
gene not previously implicated in ADHD, DBDs, aggression-
related phenotypes, or psychiatric disorders. STIM1 encodes a
transmembrane protein (STIM1) in the endoplasmatic reticulum
(ER) that acts as a sensor of calcium. Upon calcium depletion from
the ER, STIM1 is responsible for an influx of calcium ions from the
extracellular space through store-operated calcium channels to
refill ER stores52–54. Store-operated calcium entry may also be
involved in neuronal calcium signaling55, and recent evidence
indicates that STIM1 plays a role in synaptic plasticity affecting
learning and memory55,56. These results are interesting in the light
of the observed learning deficits associated with aggressive beha-
viors and accumulating evidence that suggests calcium signaling is
involved in several psychiatric disorders57–59. Alternatively, ana-
lysis of genetically regulated gene expression suggested that the
variants in the genome-wide significant locus might affect
expression of RRM1, with a decreased RRM1 expression being
associated with ADHD+DBDs. RRM1 is oriented in a tail-to-
head configuration with STIM1, which lies 1.6 kb apart, and
encodes a subunit of a reductase involved in the biosynthesis of
deoxyribonucleotides from the corresponding ribonucleotides
necessary for DNA replication. To our knowledge, this gene has
not previously been associated with psychiatric disorders.
In the gene-based analysis six genes were exome-wide sig-
nificantly associated with ADHD+DBDs, including two impli-
cated by variants in or near the genome-wide significant locus on
chromosome 11 (RRM1 and STIM1) and with three (ST3GAL3,
KDM4A, and PTPRF) out of the remaining four located in or near
the genome-wide significant locus on chromosome 1. The top-
associated genes (79 genes) seem to mainly reflect association
with the aggressive and disruptive component of the ADHD+
DBDs phenotype. The geneset was significantly associated with
ADHDwoDBDs but even more strongly associated in the
ADHD+DBDs vs. ADHDwoDBDs GWAS (where the effect of
ADHD is corrected out). Likewise, the most strongly associated
single markers (with P < 1 × 10−4) in the GWAS meta-analysis of
ADHD+DBDs showed high consistency in the direction of
association in the GWAS of ADHDwoDBDs, but even higher
consistency in the ADHD+DBDs vs. ADHDwoDBDs GWAS,
reinforcing the notion that the associations mainly reflect the
aggressive and disruptive component of the phenotype.
When evaluating the polygenic architecture of ADHD+
DBDs, a higher SNP heritability was found for ADHD+DBDs
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(h2SNP= 0.34; SE= 0.05) compared to ADHDwoDBDs (h2SNP=
0.2; SE= 0.02) (Supplementary Data 6A and 6B). These estimates
are consistent with the recently reported SNP heritability of
ADHD (h2SNP= 0.22; SE= 0.01)47, which included individuals
with and without comorbid DBDs. Conditional on an ADHD
diagnosis, the aggressive and disruptive behavioral component of
the ADHD+DBDs phenotype also has a genetic component
involving common variants (h2SNP= 0.08; SE= 0.04). PGS ana-
lyses suggested the higher SNP heritability of ADHD+DBDs
compared to ADHDwoDBDs is partly explained by a higher
burden of common ADHD risk variants (Supplementary Data 8).
The significantly higher burden of ADHD risk variants among
individuals with ADHD+DBDs was especially evident when
examining individuals belonging to the 20% of ADHD cases with
the highest ADHD genetic risk load, who had an odds ratio of
2.48 for having comorbid DBDs (Supplementary Fig. 11A). This
is also a replication of previous findings of a higher load of
ADHD risk variants in individuals with ADHD and comorbid
conduct disorder compared to those having only ADHD26.
Going beyond ADHD risk burden, the common variant
component of ADHD+DBDs could also include variants mainly
associated with aggression. This idea is supported by our finding
of increased PGS for aggression in ADHD+DBDs compared to
ADHDwoDBDs (Supplementary Fig. 11B). This conclusion is
reinforced by the genetic correlation results, where we found
somewhat higher genetic correlation of ADHD+DBDs with
both aggressive behavior in children33 and antisocial behavior34
(Supplementary Data 7) compared to those found for
ADHDwoDBDs. Additionally, these results imply that the genetic
architecture underlying the aggressive and disruptive behavioral
component of the ADHD+DBDs phenotype overlaps strongly
with that affecting aggressive and antisocial behavior in the
general population. Thus, aggressive and antisocial behaviors
seem to have a continuous distribution in the population, with
individuals having ADHD+DBDs representing an extreme. This
is in line with what has been observed for other complex phe-
notypes, such as diagnosed ADHD representing the upper tail of
impulsive and inattention behaviors47, and diagnosed autism
spectrum disorder representing the upper tail for social com-
munication difficulties and rigidity60,61.
Aggressive behavior is stable across age intervals during
childhood62, and twin studies have suggested genetics play an
important role in this stability62,63. Moreover, early aggression
might be predictive of later serious antisocial behavior64 resulting
in increased risk of a diagnosis of antisocial personality dis-
order65. Our results suggest that common genetic variants play an
important role in childhood aggression, which has also been
reported previously33, and that the subsequent risk for antisocial
behavior in individuals with ADHD+DBDs to some extent has
an underlying genetic cause involving common variants. How-
ever, our results do not reveal whether the increased polygenic
load of variants associated with aggression observed in ADHD+
DBDs is caused by variants specific to DBDs or due to a general
increased load of variants that are also shared with ADHD.
It should also be noted that the SNP heritabilities of childhood
aggression33 and antisocial behavior34 are at the low end (0.05
and 0.06, respectively), and probably biased downwards by het-
erogeneity in the cohorts analyzed33. The studies do therefore not
capture the full impact of common variants in aggressive beha-
vior, and the observed high genetic correlation of the two phe-
notypes with ADHD+DBDs involves variants that only explain
a small proportion of variance in aggression.
We have shown that individuals with ADHD+DBDs have an
increased load of variants associated with worse cognition com-
pared to individuals having ADHDwoDBDs (Supplementary
Data 8 and Supplementary Fig. 11C–F). This could reflect the
increased genetic load of ADHD risk variants in ADHD+DBDs,
since ADHD has a strong negative genetic correlation with
cognition-related phenotypes47. However, it might also involve
variants associated with antisocial behavior, which also has a
negative genetic correlation with educational performance34. This
latter idea is consistent with epidemiological studies linking
aggression to decreased educational attainment66–68. Finally, we
found a significantly higher load of variants associated with
younger age at birth of first child in ADHD+DBDs compared to
ADHDwoDBDs, in line with the observed positive genetic cor-
relations of ADHD and antisocial behavior with having children
earlier34,47 and evolutionary theories suggesting that aggression
has played a role when competing for access to mates69.
In summary, we identified three genome-wide significant loci
for ADHD+DBDs. The locus on chromosome 11 was associated
most strongly with the comorbid phenotype, and seems to be a
cross-ancestry risk locus in Europeans and Chinese. Our results
suggest that the aggressive and disruptive behavioral component
of the ADHD+DBDs phenotype has a genetic risk component,
which in part include common risk variants associated with
ADHD, aggressive, and antisocial behavior. Individuals with
ADHD+DBDs therefore represent a phenotype with an
increased genetic risk load compared to ADHDwoDBDs,
including at least one genome-wide significant locus specific to
ADHD+DBDs. This study represents the first step towards a
better understanding of the biological mechanism underlying
ADHD+DBDs.
Methods
Samples—the iPSYCH cohort. The iPSYCH cohort is a population-based nation-
wide cohort which includes 79,492 genotyped individuals (∼50,000 diagnosed with
major psychiatric disorders and ∼30,000 controls). The cohort was selected, based
on register information from a baseline birth cohort of all singletons born in
Denmark between May 1st, 1981 and December 31, 2005 (N= 1,472,762) (see a
detailed description in the ref. 70). A biological sample of the included individuals
were obtained from the Newborn Screening Biobank at Statens Serum Institute,
Denmark. DNA was extracted from dried blood spot samples and whole genome
amplified in triplicates71,72. Genotyping and calling of genotypes were performed
as described in our previous publications47,70.
For this study cases and controls were identified based on diagnoses given in
2016 or earlier in the Danish Psychiatric Central Research Register73. Cases with
ADHD+DBDs had a diagnosis of hyperkinetic conduct disorder (F90.1) or an
ADHD diagnosis (ICD-10 F90.0) occurring together with a diagnosis of ODD
(ICD-10 F91.3) or conduct disorder (ICD-10 F91.0, F91.1, F91.2, F91.8, and F91.9).
Distribution of cases with ADHD+DBDs over diagnosis codes is presented in
Supplementary Data 9. ADHD cases without DBDs were defined as individuals
having ADHD (ICD-10 F90.0) without any diagnosis of DBDs. Controls were
randomly selected from the same nation-wide birth cohort and not diagnosed with
ADHD or DBDs.
The study was approved by the Danish Data Protection Agency and the
Scientific Ethics Committee in Denmark. All analyses of the iPSYCH cohort were
performed at the secured national high performance-computing cluster,
GenomeDK (https://genome.au.dk).
Samples—cohorts from the Psychiatric Genomics Consortium. For the meta-
analysis, seven ADHD cohorts (six cohorts of European ancestry and one of
Chinese ancestry) provided by PGC with information about diagnoses of ADHD
+DBDs were included. An overview of the cohorts including genotyping infor-
mation and diagnosis criteria can be found in Supplementary Data 10. Detailed
descriptions of the cohorts can be found elsewhere74. Details on approval autho-
rities can be found in Supplementary Data 10.
Quality control and imputation. Quality control, imputation, and primary
GWASs of the iPSYCH and PGC cohorts (including the Chinese cohort) were done
separately for each using the bioinformatics pipeline Ricopili75. Pre-imputation
quality control allowed an inclusion of individuals with a call rate > 0.98 (>0.95 for
iPSYCH) and genotypes with a call rate >0.98, difference in SNP missingness
between cases and controls < 0.02, no strong deviation from Hardy–Weinberg
equilibrium (P > 1 × 10−6 in controls or P > 1 × 10−10 in cases) and low individual
heterozygosity rates (|Fhet | < 0.2). Genotypes were phased and imputed using
SHAPEIT76 and IMPUTE277 and the 1000 Genomes Project phase 3 (1KGP3)78 as
imputation reference panel (the East Asian reference genome was used for
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imputation of the Chinese sampels). Trio imputation was done with a case-
pseudocontrol setup.
Relatedness and population stratification were evaluated using a set of high-
quality genotyped markers (minor allele frequency (MAF) > 0.05, HWE P > 1 × 10−4
and SNP call rate >0.98) pruned for linkage disequilibrium (LD) resulting in ~30,000
pruned variants (variants located in long-range LD regions defined by Price et al.79
were excluded). Genetic relatedness was estimated using PLINK v1.980,81 to identify
first and second-degree relatives (π̂ > 0.2) and one individual was excluded from each
related pair (cases preferentially retained over controls). Genetic outliers were
excluded based on principal component analyses (PCA) using EIGENSOFT82,83. For
iPSYCH a genetic homogenous sample was defined based on a subsample of
individuals being Danes for three generations as described in Demontis and Walters
et al.47. For the PGC samples genetic outliers were removed based on visual
inspection of the first six PCs. For all cohorts PCA was redone after exclusion of
genetic outliers.
GWAS meta-analysis and transancestry risk in European and Chinese eth-
nicities. Association analysis was done in PLINK80 using additive logistic regres-
sion and the imputed marker dosages, covariates from principal component
analyses (after removal of genetic outliers) and other relevant covariates (Supple-
mentary Data 10). Meta-analysis of the iPSYCH cohort (2155 cases, 22,664 con-
trols) and the six PGC cohorts (1647 cases, 8641 controls) was done using an
inverse standard error weighted fixed effects model and the software METAL84 and
included in total 3802 cases and 31,305 controls.
For transancestry genetic risk variants in European and Chinese cohorts, a
GWAS meta-analysis was done as described above including the iPSYCH cohort,
the six European PGC cohorts and the cohort of Chinese ancestry. In total, 4208
cases and 32,222 controls were included. No individual genotypes were used for the
meta-analysis.
In the two meta-analyses only variants with MAF > 0.01 and imputation INFO
score > 0.8 were included. All variants that were not supported by an effective
sample size of 70% in the meta-analysis output were filtered out.
Homogeneity of effects in the PGC and iPSYCH cohorts and intercept eva-
luation. LD score regression37,38 was used to estimate the genetic correlation using
summary statistics from GWAS of ADHD+DBDs in the iPSYCH cohort and
meta-analysis of the six European PGC cohorts. Only variants with an imputation
info score > 0.9 were included. The intercept was restricted to one as there was no
sample overlap and no indication of population stratification.
The ratio (ratio= (intercept−1)/(mean χ2− 1)) from LD score regression was
used to evaluate the relative contribution of polygenic effects and confounding
factors to the observed deviation from the null in the genome-wide distribution of
the χ2 statistics of the GWAS meta-analysis of ADHD+DBDs.
Secondary GWASs. In order to adjust for the effect of ADHD we did a case-only
GWAS comparing 1,959 individuals having ADHD+DBDs against 13,539 indi-
viduals having ADHDwoDBDs, referred to as the “ADHD+DBDs vs.
ADHDwoDBDs GWAS”. Additionally, a GWAS of 13,583 cases having
ADHDwoDBDs and 22,314 population-based controls referred to as the
“ADHDwoDBDs GWAS” was performed. Both GWASs were based only on
iPSYCH samples and performed using additive logistic regression and the imputed
marker dosages, covariates from principal component analyses (after removal of
genetic outliers) and covariates indicating genotyping waves.
The summary statistics from the two secondary GWASs were used to evaluate
direction of association of the top loci associated with ADHD+DBDs using a sign
test based on LD distinct variants (r2 < 0.2, 281 variants) with association P-values
less than 1 × 10−4 in the GWAS meta-analysis of ADHD+DBDs.
We also did an mtCOJO39 analysis to estimate the effect of the top loci for
ADHD+DBDs conditional on genetic effects on ADHD alone. This was done
using summary statistics from the GWAS meta-analysis of ADHD+DBDs and
from the GWAS of ADHDwoDBDs. The analysis was run using mtCOJO39
implemented in GCTA85 using standard procedures. Following default settings,
estimation of the effect of ADHDwoDBDs on ADHD+DBDs (as part of the
indirect path contributing to marginal ADHD+DBDs associations) was
performed using variants that were genome-wide significant in the GWAS of
ADHDwoDBDs (P < 5 × 10−8), and not in linkage disequilibrium (r2 < 0.05; 7
index variants). No variants were removed due to evidence of pleiotropy (HEIDI-
outlier threshold of P= 0.01).
Gene-based association test. Gene-based association analysis was done using
MAGMA 1.0540 and summary statistics from the GWAS meta-analysis. Variants
were annotated to genes using the NCBI37.3 gene definitions and no window
around genes was used. MAGMA summarizes association signals observed for
variants located in a gene into a single P-value while correcting for LD in a
reference genome. For this the European samples from the 1000 Genomes phase 3
were used.
The most associated genes in the GWAS meta-analysis of ADHD+DBDs (79
genes, P < 10−3 Supplementary Data 4) were evaluated in a gene-set test for
association with ADHD+DBDs compared to ADHDwoDBDs and for association
with ADHDwoDBDs. Gene-based P-values were generated using summary
statistics from the two secondary GWASs (ADHD+DBDs vs. ADHD-only GWAS
and ADHDwoDBDs GWAS) and subsequently gene-set tests were done using
MAGMA 1.0540. MAGMA performs a competitive test to analyze if the gene set is
more strongly associated with the phenotype than other genes, while correcting for
a series of confounding effects such as gene length and size of the gene set.
Association of the genetically regulated gene expression with ADHD+DBDs.
Association of the genetically regulated gene expression with ADHD+DBDs was
analyzed in 12 brain tissues from GTEx86 (version 6p) using MetaXcan42 imle-
mented in the R-package metaxcanr (https://github.com/drveera/metaxcanr).
MetaXcan is an extension of PrediXcan87 that can be used to test for differences in
gene expression using summary statistics. We used high-performance prediction
models for MetaXcan based on variants located within 1Mb +/− of transcription
start site and trained using elastic net regression and 10-fold cross-validation4
downloaded from http://predictdb.org. MetaXcan also requires covariance matrices
of the variants within each gene model for each tissue. Covariance matrices cal-
culated from 503 individuals with European ancestry from the 1000 genomes
project88 available with the prediction models at http://predictdb.org were used.
SNP heritability. The SNP heritability (h2SNP) was estimated using LD score
regression37 and the summary statistics from the GWAS meta-analysis of ADHD
+DBDs. The heritability was estimated on the liability scale assuming a population
prevalence of ADHD+DBDs of 2 and 1%.
In order to evaluate the extent to which common genetic variants contributes to
the risk of ADHD+DBDs compared to having ADHDwoDBDs, the SNP
heritability of for the two phenotypes were estimated only in iPSYCH samples. This
was done using LD score regression and univariate GREML analyses in GCTA85.
h2SNP was estimated on the liability scale assuming a population prevalence of 2
and 1% for ADHD+DBDs and 3 and 4% for ADHDwoDBDs. The GCTA
analyses were corrected for the same covariates as used in the GWASs.
In order to be able to test for difference in h2SNP between ADHD+DBDs and
ADHDwoDBDs we re-estimated h2SNP using GCTA based on independent
iPSYCH controls. For this analysis the iPSYCH controls were split randomly into
two groups within each genotyping wave. One group was used as controls for
estimating h2SNP of ADHD+DBDs (2155 cases and 11,659 controls) and the other
group was used to estimate h2SNP of ADHDwoDBDs (13,583 cases and 11,250
controls). The analysis using independent controls was done using prevalances of 2
and 1% for ADHD+DBDs and 3 and 4% for ADHDwoDBDs. Test for difference
in h2SNP between ADHD+DBDs and ADHDwoDBDs was done using Eq. 1
below:




where Zdiff is the Z-score for the difference in h2SNP and SE is the standard errors
for the heritabilities. We calculated two-tailed P-values in R.
Additionally, we evaluated how much of the variance in the ADHD+DBDs
phenotype could be explained by common genetic variation in the context of
ADHD. For this we did a case-only approach including 1959 cases with ADHD+
DBDs and 13,539 individuals with ADHDwoDBDs. This was only done using
GCTA due to a low polygenic signal in the ADHD+DBDs vs. ADHDwoDBDs
GWAS (mean χ2= 1.06).
Genetic correlation with aggression-related phenotypes. The genetic overlap of
ADHD+DBDs with aggression-related phenotypes was evaluated by estimating
genetic correlations using LD score regression37 and the summary statistics from
the GWAS meta-analysis of ADHD+DBDs and results from two aggression
related GWASs. One is a GWAS meta-analysis of scores of aggressive behaviors in
18,988 children33 (EAGLE aggression) obtained by questionnaires filled by their
parents. Another is a GWAS meta-analysis of antisocial behavior conducted by the
Broad Antisocial Behavior Consortium (BroadABC) including 16,400 indivi-
duals34. Both children and adults were accessed for a broad range of antisocial
measures, including aggressive and non-aggressive domains. The BroadABC study
has a minor overlap with the EAGLE aggression GWAS with respect to the
included cohorts. We also estimated the genetic correlations of
ADHDwoDBDs and ADHD+DBDs (only including iPSYCH individuals) with the
two aggression-related phenotypes.
The genetic correlation between ADHD+DBDs and ADHDwoDBDs was
calculated using LD score regression and summary statistics from the GWAS meta-
analysis of ADHD+DBDs and the GWAS of ADHDwoDBDs, the latter based on
iPSYCH data only. To supplement the LD score regression analysis we used
iPSYCH genotypes and GCTA to estimate the genetic correlation between ADHD
+DBDs (2155 cases and 11,659 controls) and ADHDwoDBDs (13,583 cases and
11,250 controls), showing results consistent with LD score regression (rg= 0.97; SE
= 0.06), and not statistically different from one.
Statistical difference between two rg estimates was calculated using the block
jackknife method43 implemented in the LD score regression software37,89. The
variants across the genome were divided in 200 blocks and jackknife deleted values
were calculated by excluding one block at a time. The computed jackknife deleted
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values were then used to calculate corresponding jackknife pseudo values. By using
the mean and variance of the jackknife pseudovalues, Z-score and corresponding
P-values were computed, testing the null hypothesis that the difference between the
rgs is equal to zero.
Polygenic score analysis. Case-only polygenic score (PGS) analyses were done
using GWAS summary statistics from 22 GWASs related to cognition and edu-
cation (six phenotypes), personality (nine phenotypes), psychiatric disorders (five
phenotypes), reproduction/fitness (two phenotypes) (detailed list of phenotypes see
Supplementary Data 3). Variants with imputation info score < 0.9, MAF < 0.01,
missing values, ambiguous and multiallelic variants, indels and duplicated identi-
fiers were removed. The remaining variants were LD-clumped using Plink80. PGS
was estimated at different P-value thresholds in the 22 training datasets: P < 5 × 10−8,
1 × 10−6, 1 × 10−4, 1 × 10−3, 0.01, 0.05, 0.1, 0.2, 0.5, and 1.0. PGS in the target
individuals (iPSYCH samples: 1959 ADHD+DBDs cases and 13,539 ADHDwoDBDs
cases) were estimated multiplying the natural log of the odds ratio of each variant by
the allele-dosage of each variant and whole-genome PGS was obtained by summing
values over variants for each individual. The ADHD PGS was generated using the
approach described in Demontis et al.47: in short ADHD cases and controls in the
iPSYCH cohort were split into five independent samples, then one sample was left
out in an ADHD GWAS meta-analysis of iPSYCH data and data from the
Psychiatric Genetics Consortium. The results were then used as training for
generating PGS in the sample that was left out. This “leave-one sample out”
procedure was repeated until ADHD PGSs were generated for all individuals in
the iPSYCH cohort. For each P-value threshold the variance in the ADHD+
DBDs phenotype explained by PGS was estimated using Nagelkerke’s R2 (R
package “BaylorEdPsych”) and conversion to Nagelkerke’s R2 on the liability
scale was done using the method suggested by Lee et al.90 and a prevalence of
0.2 for comorbid DBDs among ADHD cases. Association of PGS with ADHD+
DBDs compared to ADHDwoDBDs was estimated using logistic regression
including the same covariates used in the GWAS.
Subsequently individuals were divided into quintiles based on their PGS. OR for
ADHD+DBDs compared to ADHDwoDBDs was estimated within each quintile
with reference to the lowest risk quintile (using the training data P-value threshold
resulting in the highest Nagelkerke’s R2 in the target data).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All relevant iPSYCH data are available from the authors after approval by the iPSYCH
Data Access Committee and can only be accessed on the secured Danish server as the
data are protected by Danish legislation. Access to data provided by the Psychiatric
Genomics Consortium can be granted through the Psychiatric Genomics Data Access
Committee https://www.med.unc.edu/pgc/about-us/people/data-access-committee/”. For
data access please contact: Ditte Demontis, email: ditte@biomed.au.dk, Anders D.
Børglum, email: anders@biomed.au.dk. The summary statistics with the results from the
GWAS meta-analysis of ADHD+DBDs are available on the iPSYCH website (https://
ipsych.dk/en/research/downloads/).
Code availability
MetaXcan analysis was performed using the R-package metaxcanr (https://github.com/
drveera/metaxcanr), and GTEx v6p expression prediction models and covariance
matrices downloaded from http://predictdb.org.
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